{"id":390738,"date":"2018-02-22T00:00:00","date_gmt":"2018-02-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0035-2018-biopharma-chronic-obstructive-pulmonary-disease-treatment-algorithms-claims-data-analysis-us-2018\/"},"modified":"2026-03-31T10:48:53","modified_gmt":"2026-03-31T10:48:53","slug":"algoim0035-2018-biopharma-chronic-obstructive-pulmonary-disease-treatment-algorithms-claims-data-analysis-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0035-2018-biopharma-chronic-obstructive-pulmonary-disease-treatment-algorithms-claims-data-analysis-us-2018\/","title":{"rendered":"Chronic Obstructive Pulmonary Disease | Treatment Algorithms | Claims Data Analysis | US | 2018"},"content":{"rendered":"<p>MARKET OUTLOOK<\/p>\n<p>Long-acting beta<sub>2<\/sub>\u00a0agonist (<abbr data-original-title=\"long-acting beta2 agonist\" title=\"\">LABA<\/abbr>)\/long-acting muscarinic antagonist (<abbr data-original-title=\"long-acting muscarinic antagonist\" title=\"\">LAMA<\/abbr>) fixed-dose combinations (<abbr data-original-title=\"fixed-dose combination\" title=\"\">FDC<\/abbr>s) are beginning to gain traction in the\u00a0<abbr data-original-title=\"chronic obstructive pulmonary disease\" title=\"\">COPD<\/abbr>\u00a0market, and both\u00a0<abbr data-original-title=\"long-acting muscarinic antagonist\" title=\"\">LAMA<\/abbr>s and\u00a0<abbr data-original-title=\"long-acting beta2 agonist\" title=\"\">LABA<\/abbr>\/inhaled corticosteroid (<abbr data-original-title=\"inhaled corticosteroid\" title=\"\">ICS<\/abbr>)\u00a0<abbr data-original-title=\"fixed-dose combination\" title=\"\">FDC<\/abbr>s are threatened by uptake of these therapies. However, many patients persist on long-acting therapies for long periods of time before switching, making it difficult for new therapies to gain a foothold. Due to the progressive and irreversible nature of\u00a0<abbr data-original-title=\"chronic obstructive pulmonary disease\" title=\"\">COPD<\/abbr>, many patients eventually end up being prescribed a combination including a\u00a0<abbr data-original-title=\"long-acting beta2 agonist\" title=\"\">LABA<\/abbr>,\u00a0<abbr data-original-title=\"long-acting muscarinic antagonist\" title=\"\">LAMA<\/abbr>, and\u00a0<abbr data-original-title=\"inhaled corticosteroid\" title=\"\">ICS<\/abbr>, but often struggle to pay for necessary treatment, which can lead to relatively low rates of compliance.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed\u00a0<abbr data-original-title=\"chronic obstructive pulmonary disease\" title=\"\">COPD<\/abbr>\u00a0patients? What are the quarterly trends in prescribing among recently-treated and newly diagnosed\u00a0<abbr data-original-title=\"chronic obstructive pulmonary disease\" title=\"\">COPD<\/abbr>\u00a0patients?<\/li>\n<li>How have\u00a0<abbr data-original-title=\"long-acting beta2 agonist\" title=\"\">LABA<\/abbr>\/<abbr data-original-title=\"long-acting muscarinic antagonist\" title=\"\">LAMA<\/abbr><abbr data-original-title=\"fixed-dose combination\" title=\"\">FDC<\/abbr>s been integrated into the treatment algorithm?<\/li>\n<li>What proportion of\u00a0<abbr data-original-title=\"chronic obstructive pulmonary disease\" title=\"\">COPD<\/abbr>\u00a0patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of\u00a0<abbr data-original-title=\"chronic obstructive pulmonary disease\" title=\"\">COPD<\/abbr>\u00a0patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug treated patients with\u00a0<abbr data-original-title=\"chronic obstructive pulmonary disease\" title=\"\">COPD<\/abbr>?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em>\u00a0provides detailed analysis of brand usage across different lines of therapy using real-world patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390738","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-obstructive-pulmonary-disease","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390738\/revisions"}],"predecessor-version":[{"id":393862,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390738\/revisions\/393862"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}